These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29276377)

  • 1. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases.
    Cantatore FP; Maruotti N; Corrado A; Ribatti D
    Biologics; 2017; 11():123-128. PubMed ID: 29276377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.
    Maruotti N; Cantatore FP; Ribatti D
    Eur J Clin Pharmacol; 2014 Feb; 70(2):135-40. PubMed ID: 24196651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments for inflammatory rheumatic disease.
    Selmi C; Generali E; Massarotti M; Bianchi G; Sciré CA
    Immunol Res; 2014 Dec; 60(2-3):277-88. PubMed ID: 25381481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Cantini F; Nannini C; Niccoli L
    Open Access Rheumatol; 2009; 1():163-178. PubMed ID: 27789989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages and angiogenesis in rheumatic diseases.
    Maruotti N; Annese T; Cantatore FP; Ribatti D
    Vasc Cell; 2013 Jun; 5(1):11. PubMed ID: 23725043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies.
    Cabral VP; Andrade CA; Passos SR; Martins MF; Hökerberg YH
    Rev Bras Reumatol Engl Ed; 2016; 56(6):543-550. PubMed ID: 27914602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
    Salliot C; Dougados M; Gossec L
    Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological therapy for the treatment of rheumatic diseases].
    Pierer M; Baerwald C
    Internist (Berl); 2008 Aug; 49(8):938-46. PubMed ID: 18587545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL; Arkema EV; Glintborg B; Mehnert F; Østergaard M; Dreyer L; Nørgaard M; Krogh NS; Askling J; Hetland ML;
    Ann Rheum Dis; 2019 Mar; 78(3):320-327. PubMed ID: 30612115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
    PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapies and bone loss in rheumatoid arthritis.
    Zerbini CAF; Clark P; Mendez-Sanchez L; Pereira RMR; Messina OD; Uña CR; Adachi JD; Lems WF; Cooper C; Lane NE;
    Osteoporos Int; 2017 Feb; 28(2):429-446. PubMed ID: 27796445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.
    Atzeni F; Talotta R; Masala IF; Gerardi MC; Casale R; Sarzi-Puttini P
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):500-510. PubMed ID: 31174819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.